Le Lézard
Classified in: Health, Science and technology, Business
Subjects: ACC, CXP, MAT

KALY Confirms Consolidation Plans to Focus on $50 Billion Cannabis Biopharmaceutical Market Opportunity


DALLAS, Jan. 15, 2020 /PRNewswire/ -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) ("KALY") today confirmed plans announced for the first time yesterday to consolidate its business structure and focus on its Cannabis Biopharmaceutical Technology. KALY has a U.S. Patented Cannabis Extraction Process and is developing treatments for various medical conditions.  The technology has been valued at $50 million in conjunction with a recent acquisition offer that ALYI management passed on. In reaction to the offer, management has refined its ongoing business plans with the intent of consolidating and concentrating focus on its Cannabis Biopharmaceutical Technology. The cannabis biopharmaceutical market is anticipated to reach $50 billion by 2029. In conjunction with the consolidation, management plans to spin-off its other lines of business. Specifically, ALYI plans to spin-off its general agricultural CBD extraction business and CBD confections business. While ALYI will continue to generate licensing revenue from the extraction and confection businesses, the day to day management and operations will be spun-off. A specific spin-off structure has not yet been defined. Spin-off details are anticipated to be released next month.

To stay abreast of the latest developments and learn more about the company visit  https://www.kali-extracts.com/.

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and as such, may involve risks and uncertainties. These forward looking statements relate to, amongst other things, current expectation of the business environment in which the company operates, potential future performance, projections of future performance and the perceived opportunities in the market. The company's actual performance, results and achievements may differ materially from the expressed or implied in such forward-looking statements as a result of a wide range of factors.

CONTACT:
Frederick Ferri
ir@kali-extracts.com
+1(214) 210-0459

SOURCE Kali-Extracts, Inc.


These press releases may also interest you

at 09:45
The "Top 10 Cancer Drugs Market by Region: Opportunity Analysis and Industry Forecast, 2018-2026" report has been added to ResearchAndMarkets.com's offering. According to the report, the top 10 cancer drugs market accounted for $63,619 million in...

at 09:35
Nymox Pharmaceutical Corporation is pleased to announce that a new peer review report was published today in the World Journal of Urology, documenting the successful long-term clinical trial results after Fexapotide Triflutate treatment for early...

at 09:30
According to the new market research report "Sterile Filtration Market by Product (Cartridge, Capsule, Syringe), Application (Fill Finish Process, Bioburden Reduction), Membrane (Nylon, PTFE, PES, PVDF), Pore Size (0.2 Microns), End User...

at 09:30
Shift in procedures for aortic stenosis and mitral regulation continue to drive robust growth in structural heart devices market. The technical advancements in healthcare procedures continue to make way for minimally-invasive methods, which are ideal...

at 09:25
Generex Biotechnology Corporation (www.generex.com) ("Generex") today announced that FINRA has officially posted the Generex 2:5 stock dividends in Generex and NuGenerex...

at 09:25
The "Laboratory Automation Market by Product Type Application and End User: Global Opportunity Analysis and Industry Forecast, 2019-2026" report has been added to ResearchAndMarkets.com's offering. The global laboratory automation market was valued...



News published on 15 january 2020 at 08:00 and distributed by: